We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+43.87%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$6.69B
AUM Growth
+$1.28B
Cap. Flow
+$331M
Cap. Flow %
4.95%
Top 10 Hldgs %
72.51%
Holding
39
New
–
Increased
16
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$156M
2
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$47.3M
3
KYMR icon
Kymera Therapeutics
KYMR
+$44.8M
4
ASND icon
Ascendis Pharma A/S
ASND
+$29M
5
APLS
Apellis Pharmaceuticals
APLS
+$26.5M

Top Sells

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$15.6M
2
UTHR icon
United Therapeutics
UTHR
+$15.5M
3
RLAY icon
Relay Therapeutics
RLAY
+$8.95M
4
AMRN
Amarin Corp
AMRN
+$6.54M
5
KURA icon
Kura Oncology
KURA
+$6.11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$25.9B
$797M 11.91%
2,865,000
-61,500
-2% -$15.5M
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$797M 11.9%
7,000,000
+1,875,000
+37% +$156M
APLS
3
DELISTED
Apellis Pharmaceuticals
APLS
$549M 8.21%
10,625,000
+500,000
+5% +$26.5M
MDGL icon
4
Madrigal Pharmaceuticals
MDGL
$12.4B
$482M 7.2%
1,660,000
+125,000
+8% +$12.2M
ARGX icon
5
argenx
ARGX
$54.9B
$479M 7.16%
1,265,555
– –
SRPT icon
6
Sarepta Therapeutics
SRPT
$1.64B
$411M 6.15%
3,175,000
– –
ASND icon
7
Ascendis Pharma A/S
ASND
$16.6B
$379M 5.66%
3,100,000
+250,000
+9% +$29M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$11.9B
$368M 5.5%
3,555,555
– –
FOLD
9
DELISTED
Amicus Therapeutics
FOLD
$327M 4.89%
26,800,000
– –
ALNY icon
10
Alnylam Pharmaceuticals
ALNY
$38.1B
$263M 3.92%
1,105,000
– –
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$252M 3.76%
5,555,555
+5,000
+0.1% +$324K
SGEN
12
DELISTED
Seagen Inc. Common Stock
SGEN
$242M 3.62%
1,885,000
+20,000
+1% +$2.58M
XENE icon
13
Xenon Pharmaceuticals
XENE
$6.15B
$193M 2.89%
4,900,000
– –
ISEE
14
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$145M 2.16%
6,750,000
+850,000
+14% +$18.1M
KRYS icon
15
Krystal Biotech
KRYS
$10.6B
$112M 1.67%
1,410,000
+135,000
+11% +$10M
BCRX icon
16
BioCryst Pharmaceuticals
BCRX
$2.43B
$104M 1.55%
9,050,000
– –
KYMR icon
17
Kymera Therapeutics
KYMR
$8.6B
$96.1M 1.44%
3,850,000
+1,680,770
+77% +$44.8M
DICE
18
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$78.8M 1.18%
2,525,555
+1,450,555
+135% +$47.3M
SNDX icon
19
Syndax Pharmaceuticals
SNDX
$1.68B
$67.4M 1.01%
2,650,000
+427,778
+19% +$9.98M
CBAY
20
DELISTED
Cymabay Therapeutics
CBAY
$64.6M 0.97%
10,300,000
– –
MNKD icon
21
MannKind Corp
MNKD
$1.2B
$48M 0.72%
9,100,000
– –
NUVL
22
DELISTED
Nuvalent
NUVL
$46.3M 0.69%
1,555,555
+506,084
+48% +$14.1M
RNAM
23
DELISTED
Avidity Biosciences
RNAM
$45.5M 0.68%
2,050,000
+600,000
+41% +$8.95M
IOVA icon
24
Iovance Biotherapeutics
IOVA
$2.03B
$44.9M 0.67%
7,020,000
-2,000,000
-22% -$15.6M
MRSN
25
DELISTED
Mersana Therapeutics
MRSN
$44.2M 0.66%
302,000
– –
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q4 2022 Portfolio in Review

As of Q4 2022, Avoro Capital Advisors held 39 positions worth $6.69B, up 24% from $5.41B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Avoro Capital Advisors deployed $331M of net new capital in Q4 2022, adding to 16 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Iovance Biotherapeutics, an estimated $15.6M trimmed.

  • Avoro Capital Advisors added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022, an estimated $156M increase.
  • Avoro Capital Advisors's biggest Q4 2022 reduction was Iovance Biotherapeutics, cutting an estimated $15.6M.
  • Avoro Capital Advisors fully exited Relay Therapeutics in Q4 2022, selling an estimated $8.95M.
  • Avoro Capital Advisors's ten largest holdings make up 73% of its $6.69B portfolio in Q4 2022.
  • Avoro Capital Advisors opened 0 new positions and closed 3 in Q4 2022.
  • Avoro Capital Advisors's portfolio value rose 24% quarter-over-quarter to $6.69B.

Based on Avoro Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.